#ESMORareCancers26: ARCAGEN highlights a gap between molecular profiling and treatment in advanced #RareCancers. Among patients with clinically actionable alterations, only 15% received matched targeted therapy or #immunotherapy.
#ESMODailyReporter 📌 https://ow.ly/bjjH50YFB8j

5.1 million people across Europe are living with rare cancers, highlighted by a pink map of European countries.

#RareDiseases & #RareCancers are not separate worlds - patients face similar challenges, from diagnosis to access to care.

Through the Rare Cancer Advocates Network, EURORDIS is working to improve outcomes and ensure no patient is left behind. 👉 Read more: https://go.eurordis.org/rarecancers

#Cancer52BigConversation, #rarecancers charities discussing UK cancer policy. The State of the Nation Report: No Cancer Too Rare, holding the government accountable & improvements for patients.

Full report: e2236186-a9de-45db-b8f6-3f2d6db40cb4.usrfiles.com...

#Cancer52 #PseudomyxomaSurvivor

All #pediatric #cancers are #rarecancers and there are MANY of them, per @seattlechildrens.org pathologist Dr. Christopher Sande, who focuses on soft tissue #sarcomas. And MANY of these cancers have subtypes. #rarecancersymposium @fredhutch.org #CanSky

TRACER The Transformative Rare Cancer initiative (TRACER) at Fred Hutchinson Cancer Center is founded on four fundamental pillars, each crucial to our mission’s success:​ engaging the community, developing v...

Learning abt #rarecancers at @fredhutch.org's Rare Cancer Patient Symp, sponsored by #TRACER, #Seattle Translational Tumor Research program, rarecancerprogram.com

"If we work in silos, the progress will be too slow. Collaboration has 2B the foundation of our effort." ❤️
- Dr. Taran Gujral
#CanSky

🤝On 25–26 February 2026, CPE participated in the first in-person meeting of the ImmuneT-Me consortium at Uniklinik Köln in Cologne.

🔗 Learn more: cancerpatientseurope.org/immunet-me-c...

#CancerResearch #RareCancers #PatientEngagement #PersonalisedMedicine

🏆 Congratulations to the #ESMOMeritAward recipients at #ESMORareCancers26

These young researchers were recognised for the scientific merit of their abstracts.

🔗https://ow.ly/CPuX50YsfWE
#RareCancers #Oncology #Sarcoma

💪 We continue our strong EORTC presence at #ESMORareCancers26, sharing new evidence on QoL, molecular profiling and treatment innovation in rare cancers.

Tomorrow, look out for Tetsuya Sekita’s poster on surgical quality in retroperitoneal liposarcoma.

#EORTC #RareCancers

In #RareCancers, guidelines are vital to bring together scattered expertise. A recent EURACAN survey highlights a high uptake of recommendations from oncologists, potentially leading to improved patients’ survival.
#ESMORareCancers26 #ESMODailyReporter
📌 https://ow.ly/nooJ50YsIQ9

World Cancer Day: United by Unique in Rare Cancer Care Honoring World Cancer Day 2026 with expert insights on rare cancers, patient resources, and advocacy efforts.

🌍 Flashback to #WorldCancerDay and this year’s theme “United by Unique.”

#RareCancers remind us that no two cancer journeys are the same. Patient-centered care and clinician insight remain essential across #Oncology and #RareDisease.

🔗 https://bit.ly/4tXPn2O

#RareDiseaseDay

🎗️ February marked Gallbladder & Bile Duct Cancer Awareness Month, highlighting #Cholangiocarcinoma.

Often diagnosed at advanced stages, with limited early detection.

#RareCancers remain part of the broader #Oncology landscape.

🔗 https://bit.ly/3KQY0tS

#RareDiseaseDay #RareDisease

World Cancer Day: United by Unique in Rare Cancer Care Honoring World Cancer Day 2026 with expert insights on rare cancers, patient resources, and advocacy efforts.

🌍 Today is World Cancer Day

The 2025–2027 theme “United by Unique” highlights people-centered care and the unique journey of every cancer patient. @uiccofficial.bsky.social

Read our collection of articles on #RareCancers: https://bit.ly/4qg1tkK

#WorldCancerDay #RareCancer #MedSky

“The 5-year survival rate is lower for rare cancer patients compared to those with common cancers. Feb 28, 2026. #RareDiseaseDay.” A blue and purple gradient background with bold white text. The Rare Disease Day logo (multicoloured hand) appears in the top left.

🎗️ Rare cancers often receive less attention, leaving patients and families with fewer options and more uncertainty. Equal funding isn’t enough.

💜 Equity for rare diseases means fair funding, equal care & real hope for all.

#RareDiseaseDay #EquityForRare #RareCancers #WorldCancerDay

Donate to Support Jess and Andy through this unimaginable diagnosis, organized by Alexandra Forssman Our beautiful Jess, our sister, daughter, devoted mum, soulma… Alexandra Forssman needs your support for Support Jess and Andy through this unimaginable diagnosis

gofund.me/33330e0f7 #KCC #fcancer #rarecancers

This underscores the need for precision medicine in treating rare GC subtypes: hepatoid, medullary with lymphoid stroma, Paneth cell, salivary gland, squamous, adenosquamous, neuroendocrine, gastroblastoma. With scarce evidence, it urges personalized treatment into practice.
#RareCancers

Such a wonderful gift for everyone in the UK with ACC 💚🙏 www.accsupport.org.uk #ACC #adrenocorticalcancer #rarecancers

Datenbank seltene BRAF-Mutationen: Heidelberg University Hospital Datenbank seltene BRAF-Mutationen

New tool maps rare #BRAF #melanoma mutations to outcomes. 130 patients, 23 variants & System Usability Score of 92.5. Data is open via R/Shiny, adaptable to other #RareCancers. Precision oncology just got smarter! www.klinikum.uni-heidelberg.de/en/hautklini...

#OncBluesky #PrecisionMedicine #CanSky

Significant new results from ONJCRI’s Phase II rare cancer clinical trial on combination immunotherapy in dMMR/MSI-H non-colorectal cancers have been published in @jamaoncology.com.

➡️ Learn more: jamanetwork.com/journals/jam...

#RareCancers #RareCancerTrial #ClinicalTrials #ONJCRI

Bright yellow graphic with large blue quotation mark. Text reads: “Drug repurposing can play an important role in ensuring faster and affordable access to new treatments and innovation in any type of disease. It can have a crucial role in all rare cancers, such as sarcomas, and in particular for paediatric patients or adolescent and young adults (AYA) where sarcomas are more common.” — Ornella Gonzato & Roger Wilson. Bottom corner includes the text “Read more” and link bit.ly/SPAGNblog_DrugRepurpose.

Repurposing existing drugs could open new treatment paths for rare cancers like sarcoma. Learn why SPAGN's Ornella Gonzato and Roger Wilson believe this is an urgent opportunity for our community.
Read the blog: www.sarcoma-patients.org/blog/drug_re...

#Sarcoma #RareCancers #DrugRepurposing

Networking Support Scheme - ERDERA ERDERA's Networking Support Scheme helps promote knowledge sharing on rare diseases and rare cancers through the funding of events. It also encourages the participation from underrepresented European countries in networks.

Round 2 of ERDERA’s Networking Support Scheme is open! Apply for funding to host transnational events that boost collaboration, research uptake and knowledge sharing in #RareDiseases and #RareCancers.
👉 See more: https://loom.ly/scOFS9w

Drug repurposing: What is it? And why the sarcoma community should be interested in it - SPAGN - Sarcoma Patient Advocacy Global Network An ongoing review of pharmaceutical regulations at the European Union’s level has the potential to unleash therapeutic innovations through drug repurposing. If approved, drug development could be…

New uses for existing drugs offer a faster, smarter way to advance sarcoma treatments. At SPAGN we’re backing reform and non-profit innovation so patients benefit.

Our latest blog: www.sarcoma-patients.org/blog/drug_re...

#Sarcoma #RareCancers #PatientAdvocacy #DrugRepurposing

Our CEO Lynsey Conway & Treasurer Geoff Otterman represented ALK+ UK at the @cancer52org.bsky.social parliamentary reception at the House of Lords - bringing attention to rare & less common cancers & the need for stronger inclusion in the National Cancer Plan.

#LCSM #LungCancer #RareCancers

#ESMO25: Innovative strategies produced mixed results in #RareCancers, but encouraging efficacy was demonstrated with #immunotherapy in Merkel-cell carcinoma and with belzutifan in phaeochromocytoma and paragangliomas.
More in the #ESMODailyReporter 📌 https://ow.ly/7GP350XjGXX

#ESMO25: Early results with two novel #immunotherapies in advanced neuroendocrine carcinoma (#NEC) suggest greater efficacy versus chemotherapy alone but with higher toxicity #ESMODailyReporter 🔗 https://ow.ly/I4x150XjCwR

#RareCancers

#ESMO25: Arthur Braat discusses the use of radiopharmaceuticals in advanced gastroenteropancreatic neuroendocrine tumours (#NETs) with reference to several studies presented in Berlin. Read more in the #ESMODailyReporter 👉 https://ow.ly/G5yW50XjyWv

#RareCancers

#ESMO25: In #thymic epithelial tumours, rivoceranib after prior therapy and peri-operative pembrolizumab demonstrated promising efficacy but were not superior to standard therapies. Read more in the #ESMODailyReporter 📌 https://ow.ly/22ES50XiaXb

#RareCancers

What about phyllodes tumor? Dutch patient advocates honored for pioneering work to develop treatment guidelines - SPAGN - Sarcoma Patient Advocacy Global Network This year, SPAGN awarded the third prize of Advocacy in Action Award to the Patiënten Platform Sarcomen in the Netherlands for their project on the management of phyllodes tumors, a rare form of…

Meet Dutch patient-advocate Marloes van Esterik. Her journey with a borderline phyllodes breast tumour sparked the creation of a national patient group and a push for formal protocols.

More in SPAGN's latest blog: www.sarcoma-patients.org/blog/what_ab...

#Sarcoma #PhyllodesTumor #RareCancers

Networking Support Scheme - ERDERA ERDERA's Networking Support Scheme helps promote knowledge sharing on rare diseases and rare cancers through the funding of events. It also encourages the participation from underrepresented European countries in networks.

Round 1 of ERDERA’s Networking Support Scheme has closed.
But good news — Round 2 is now open! Apply for funding to host transnational events that boost collaboration, research uptake and knowledge sharing in #RareDiseases and #RareCancers.
👉 See more: https://loom.ly/scOFS9w

Rare Cancer Day 2025: Illuminating the Hidden Frontiers of Oncology - OncoDaily Rare Cancer Day 2025: Illuminating the Hidden Frontiers of Oncology / Adrenal Cortical Carcinoma, cancer, Cancer research, cholangiocarcinoma, Ewing sarcoma,

Rare Cancer Day 2025: Illuminating the Hidden Frontiers of Oncology

oncodaily.com/blog/rare-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #RareCancerDay

Excited to share that our Patient Engagement Director, Rachel Giles, co-authored a Cancer Treatment Reviews article on overcoming barriers for #RareCancers in the era of #PrecisionOncology. 📄 Read here: www.cancertreatmentreviews.com/article/S030...